Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 131.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.50M |
| Shares Out | 66.39M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,962 |
| Open | 1.57 |
| Previous Close | 1.56 |
| Day's Range | 1.52 - 1.57 |
| 52-Week Range | 1.18 - 6.77 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | 3.77 (+146.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 3.77, which is an increase of 146.41% from the latest price.
News
Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights
Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital
WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Cap...
Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate
The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in ...
New Strong Sell Stocks for August 24th
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)
Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer
Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LON...
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021
7 Reddit Penny Stocks to Watch For the Long Weekend
With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information |...
Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?
Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?
Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwrit...
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the c...
Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday
Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the p...
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor)
Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?
Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business...
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on Ma...
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Develo...
Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology
Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Resul...
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support f...
The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel
Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher
Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...